Neurological Surgery 脳神経外科41巻9号

2013年09月発行

連載 脳神経外科手術手技に関する私見とその歴史的背景

11．Gliomaの治療--手術的治療を中心にして

著者： 米川泰弘¹

所属機関： ¹University of Zürich

ページ範囲：P.817 - P.837

Ⅰ．はじめに

　筆者は，1993年にZürich大学脳神経外科主任教授に着任した後，2007年5月の退官の期日をはさんで2011年末までにgliomaの手術を1,036回行った（Fig.1）．これは同じ期間の脳動脈瘤の手術1,039回に匹敵する回数である．その間に前者は，治療的には放射線療法（radiotherapy：RT），化学療法（chemotherapy）の発展，手術的には術中MRI，navigationなどの発達があり，後者は，endovascular surgeryの発展で治療の様相が変わり，その治療成績はともに改善してきたといえる．

　本稿では，筆者が経験してきた自執刀glioma症例についての成績，そのfollow-up，印象をcase report的に提示し，種々の技術的，治療的問題点，それらの歴史的な変遷にも言及するが，読者の日常診療のご参考になれば幸いである．

参考文献

1) Bernays RL, Imhof HG, Yonekawa Y：Intraoperative Imaging in Neurosurgery：MRI, CT, Ultrasound. Springer, Wien, New York, 2003

2) Brandes AA, Franceschi E, Tosoni A, Pession A, Blatt A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M：MGMT promoter methylation status can be predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26：2192-2197, 2008

3) Burkhard C, Di Patre PL, Schüler D, Schüler G, Yaşargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H：A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg 98：1170-1174, 2003

4) Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Z, Ramsaz DA, Louis DN：Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90：1473-1479, 1998

5) Deb P, Sharma MC, Chander B, Mahapatra AK, Sarkar C：Giant cell glioblastoma multiforme：report of a case with prolonged survival and transformation to gliosarcoma. Childs Nerv Syst 22：314-319, 2006

6) Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Mauses De Paula A, Fernandez C, Bouvier C：Histological and molecular classification of gliomas. Rev Neurol（Paris）164：505-515, 2008

）than in secondary glioblastomas. Lab Invest 80：65-72, 2000

8) Fukushima S, Narita Y, Miyakita Y, Ohno M, Takizawa T, Takusagawa Y, Mori M, Ichimura K, Tsuda H, Shibui S：A case of more than 20 years survival with glioblastoma, and development of cavernous angioma as a delayed complication of radiotherapy. Neuropathology 2013 Feb 13（epub ahead of print)

9) Fuller GN, Ribalta T：Brain tumors：An overview of current histopathologic classifications. In Winn HR（ed）：Youmans Neurological Surgery, Vol 2, Elsevier, Philadelphia, 2011, pp1077-1086

10) Grahovac G, Tomac D, Lambasa S, Zoric A, Habek M：Cerebellar glioblastomas：pathophysiology, clinical presentation and management. Acta Neurochir（Wien）151：653-657, 2009

11) Hegedüs K, Molnár P：Primary cerebellar glioblastoma multiforme with an unusually long survival. Case report. J Neurosurg 58：589-592, 1983

12) Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Heinfellner JA, Mason W, Mariani L, Bromberg JEC, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp Ret：MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352：997-1003, 2005

13) Hempel V：Untersuchung über die Bedeutung des Tumorsitzes für die Prognose der Glioblastomerkrankung. Inaugural-Dissertation der Universität Zürich, 1968

14) Hofer S：Neuroonkologie-neue Therapiestrategien. Therapeutische Umschau 69：597-604, 2012

15) Homma T, Fikushima T, Vaccarella S, Yonekawa Y, di Patre PL, Franceschi S, Ohgaki H：Correlation among pathology, genotype and patient outcomes in glioblastoma. J Neuropath Exp Neurol 65：846-854, 2006

16) Jacobi CA, Menenakos C, Braumann C：Taurolidine--a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 16：917-921, 2005

17) Juratli TA, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schackert G, Krex D：The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 110：325-333, 2012

18) Kehl R：Ergebnisse der Extirpation von Glioblastomen mit Hilfe der mikrotechnischen Operationsmethode. Inaugural-Dissertation der Universität Zürich, 1978

19) Kelly PJ：Gliomas：Survival, origin and early detection. Surg Neurol Int 2010, Dec 25；1：96, DOI：10. 4103/2152-7806.74243

）and secondary glioblastomas. Acta Neuropathol（Berl）113：295-302, 2007

21) Kleihues P, Cavenee WC（eds）：Pathology ＆ Genetics；Tumor of the nervous system. IARC Press, Lyon, 2000

22) Klein R, Mölenkamp G, Sörensen N, Roggendorf W：Favorable outcome of giant cell glioblastoma in a child. Report of an 11-year survival period. Childs Nerv Syst 14：288-291, 1998

23) Kozak KR, Moody JS：Giant cell glioblastoma：a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol 11：833-841, 2009

24) Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S；Glioma Outcomes Investigators：Survival following surgery and prognostic factors for recently diagnosed malignant glioma：data from the Glioma Outcome Project. J Neurosurg 99：467-473, 2003

25) Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P：The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 114：97-109, 2007

26) Maguire JA, Thiessen B, Moore W, Miller M, Leung E, Horsman D：Giant cell glioblastoma：predictive and prognostic factors. J Neuropathol Exp Neurol 66：426-427, 2007

27) Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Boström J, Wiestler OD, Louis DN, Reifenberger G, von Deimling A：Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 151：853-857, 1997

28) Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H：Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81：77-82, 2001

29) Ohgaki H, Watanabe K, Peraud A, Biernat W, von Deimling A, Yaşargil MG, Yonekawa Y, Kleihues P：A case history of glioma progression. Acta Neuropathol 97：525-532, 1999

30) Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yaşargil MG, Lütolf UM, Kleihues P：Genetic pathways to glioblastoma：a population-based study. Cancer Res 64：6892-6899, 2004

31) Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H：Genetic profile of the giant cell glioblastoma. Lab Invest 79：123-129, 1999

32) Quinones-Hinojosa A, Kosztowski T, Brem H：Malignant glioma：Anaplastic Astrocytoma, Glioblastoma Multiforme, Gliosarcoma. In Winn HR（ed）：Youmans Neurological Surgery, Vol 2, Elsevier, Philadelphia, 2011, pp1327-1340

33) Rodak R, Kubota H, Ishihara H, Eugster HP, Könü D, Möhler H, Yonekawa Y, Frei K：Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 102：1055-1068, 2005

34) Sanai N, Chang S, Berger MS：Low-grade gliomas in adults. J Neurosurg 115：948-965, 2011

35) Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V：Intraoperative MRI guidance and extent of resection in glioma surgery：a randomised, controlled trial. Lancet Oncol 12：997-1003, 2011

36) Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ：Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins：a prospective study in 52 consecutive patients. J Neurosurg 93：1003-1013, 2000

37) Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff Ro；European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups；National Cancer Institute of Canada Clinical Trials Group：Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352：987-996, 2005

38) Sure U, Rüedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME：Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 56：782-789, 1997

39) 髙倉公朋：脳腫瘍（髙倉公朋，阿部　弘（編）：New脳神経外科学，南江堂，1999, pp175-238）

40) Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, Kleihues P, Ohgaki H：PTEN（MMAC1）mutations are frequent in primary glioblastomas（de novo）but not in secondary glioblastomas. J Neuropathol Exp Neurol 57：684-689, 1998

41) Utsuki S, Oka H, Miyajima Y, Kijima C, Yasui Y, Fujii K：Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma. Brain Tumor Pathol 29：87-95, 2012

42) 渡●学郎，吉野篤緒，片山容一：神経膠腫における遺伝子解析とテーラーメイド治療．No Shinkei Geka 33：537-553, 2005

43) Weller W（ed）：Empfehlungen zur Diagnostik, Therapie und Nachsorge bei Hirntumorerkrankungen. UniversitätsSpital Zürich, 2011

44) Westphal M：Classification of brain tumors and corresponding treatments. In Sindou M（ed）：Practical handbook of neurosurgery. Springer, Wien, NewYork, 2009, Vol.2, pp3-28

45) Yonekawa Y：How to perform selective extradural anterior clinoidectomy. In Sindou M（ed）：Practical Handbook of Neurosurgery. Springer, Wien, NewYork, 2009, Vol.1, pp155-166

46) 米川泰弘：4．選択的扁桃体海馬摘除術（脳神経外科手術手技に関する私見とその歴史的背景）．No Shinkei Geka 35：1183-1196, 2007

47) 米川泰弘：6．体位，手術器具（脳神経外科手術手技に関する私見とその歴史的背景）．No Shinkei Geka 38：381-396, 2009

48) 米川泰弘：7．アプローチ再考（脳神経外科手術手技に関する私見とその歴史的背景）．No Shinkei Geka 38：1031-1045, 2010

49) 米川泰弘：8．後頭下開頭（suboccipital craniotomy：SOC）留意点とその対象疾患（脳神経外科手術手技に関する私見とその歴史的背景）．No Shinkei Geka 39：789-809, 2011

50) 米川泰弘：10．MicroneurosurgeryとPETscan：一脳神経外科医の経験から（脳神経外科手術手技に関する私見とその歴史的背景）．No Shinkei Geka 40：823-846，2012